Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia.

• Outcomes of lymphoid blast phase chronic myeloid leukemia were still poor. • TKI-BCL-2 inhibitors-hypomethylating agents induced fast and deep response in patients with chronic myeloid leukemia. • This protocols also had mild adverse events, including hematological toxicity. [ABSTRACT FROM AUTHOR]